- ISIN
- US55287L1017
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Sep 13, 2024
Highlights
- Market Cap
- $2.92B
- Enterprise Value
- $2.87B
- EPS (TTM)
- -$2.22
- Gross Profit (TTM)
- -$160.00K
- EBITDA (TTM)
- -$96.31M
- Year Range
- $9.63 - $66.66
- Target Price
- $55.33
- ROA (TTM)
- -19.13%
- ROE (TTM)
- -19.78%
- Avg. Volume (1M)
- 839K
- Avg. Volume Value (1M)
- $49.81M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
MBX Performance Chart
MBX Biosciences, Inc (MBX) is up 94.4% since the beginning of the year. At $61 per share, MBX is trading 8.0% below its 52-week high of $67.
Loading charts...
Returns By Period
MBX Biosciences, Inc (MBX) has returned 94.36% so far this year and 320.73% over the past 12 months.
MBX Biosciences, Inc
- 1D
- -1.13%
- 1M
- 17.19%
- 6M
- 67.49%
- YTD
- 94.36%
- 1Y
- 320.73%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- 69.05%
Benchmark (S&P 500 Index)
- 1D
- 0.21%
- 1M
- 1.02%
- 6M
- 6.45%
- YTD
- 8.52%
- 1Y
- 16.26%
- 3Y*
- 17.48%
- 5Y*
- 10.95%
- 10Y*
- 13.08%
- ALL TIME*
- 8.07%
MBX Monthly Returns History
Based on dividend-adjusted daily data since Sep 13, 2024, MBX's average daily return is +0.44%, while the average monthly return is +7.34%. At this rate, an investment would double in approximately 0.8 years.
Historically, 57% of months were positive and 43% were negative. The best month was Jun 2026 with a return of +75.4%, while the worst month was Jan 2025 at -45.7%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 6 months.
On a daily basis, MBX closed higher 52% of trading days. The best single day was Sep 22, 2025 with a return of +100.0%, while the worst single day was Feb 10, 2025 at -16.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 16.84% | -11.67% | -8.29% | 1.24% | 4.14% | 75.41% | 11.05% | 94.36% | |||||
| 2025 | -45.69% | -4.10% | -23.12% | 42.14% | 18.40% | -8.13% | 16.13% | 13.89% | 15.97% | 25.49% | 57.06% | -8.55% | 71.13% |
| 2024 | 12.96% | -11.86% | -11.18% | -9.39% | -19.87% |
Benchmark Metrics
MBX Biosciences, Inc has an annualized alpha of 139.81%, beta of 1.47, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since September 13, 2024.
- This stock captured 192.34% of S&P 500 Index gains and tended to rise during its downturns (downside capture of -136.83%) - a profile typical of hedging or uncorrelated assets.
- R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 139.81%
- Beta
- 1.47
- R²
- 0.04
- Upside Capture
- 192.34%
- Downside Capture
- -136.83%
Return for Risk
Risk / Return Rank
MBX ranks 96 for risk / return — in the top 96% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for MBX Biosciences, Inc (MBX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| MBX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.13 | ||
| Sortino ratioReturn per unit of downside risk | +2.06 | ||
| Omega ratioGain probability vs. loss probability | 1.45 | 1.23 | +0.22 |
| Calmar ratioReturn relative to maximum drawdown | 8.59 | 1.80 | +6.79 |
| Martin ratioReturn relative to average drawdown | 16.44 | 7.70 | +8.73 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the MBX Biosciences, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the MBX Biosciences, Inc was 77.71%, occurring on Apr 8, 2025. Recovery took 155 trading sessions.
The current MBX Biosciences, Inc drawdown is 6.71%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-77.71%Apr 2025 | 6mo 9d | 7mo 14d | 1y 1moOct 2024 - Nov 2025 | 2025 selloff2025 |
-37.60%Mar 2026 | 2mo 8d | 2mo 24d | 5mo 2dJan 2026 - Jun 2026 | — |
-19.69%Dec 2025 | 16d | 5d | 21dDec 2025 - Dec 2025 | — |
-17.53%Jan 2026 | 14d | 6d | 20dDec 2025 - Jan 2026 | — |
-13.88%Jul 2026 | 4d | — | 19dJul 2026 - now | — |
Drawdown Indicators
| MBX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -77.71% | -56.78% | -20.93% |
Max Drawdown (1Y)Largest decline over 1 year | -37.60% | -9.10% | -28.50% |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -6.71% | -2.38% | -4.33% |
Average DrawdownAverage peak-to-trough decline | -32.93% | -10.70% | -22.23% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 19.62% | 2.12% | +17.50% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of MBX Biosciences, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how MBX Biosciences, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for MBX in comparison with other companies in the Biotechnology industry. Currently, MBX has a P/B value of 6.5. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with MBX
Add MBX Biosciences, Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with MBX